Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdR-siPTEN
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Parenteral
01
Overview
**AdR-siPTEN** is an experimental recombinant adenoviral vector engineered to express a small interfering RNA directed against **phosphatase and tensin homolog**. It is intended to suppress PTEN expression following local central nervous system administration. In rat migraine models, spinal trigeminal nucleus administration reduced markers associated with trigeminal nociceptive activation, including NR2B signaling, nitric oxide synthase, nitric oxide, and c-Fos. The construct has been reported only in preclinical rat studies of migraine and has no identified clinical development program, manufacturer, marketed name, or assigned INN.
- Other names
- adenovirus-expressing siPTENAdR-siPTENrecombinant adenovirus AdR-siPTEN
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)
Beyond the preview
Go deeper on AdR-siPTEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdR-siPTEN.